Large-scale testing (Phase 3)Study completedNCT01339923
What this trial is testing
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,409